HRP20110015T1 - DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI - Google Patents
DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI Download PDFInfo
- Publication number
- HRP20110015T1 HRP20110015T1 HR20110015T HRP20110015T HRP20110015T1 HR P20110015 T1 HRP20110015 T1 HR P20110015T1 HR 20110015 T HR20110015 T HR 20110015T HR P20110015 T HRP20110015 T HR P20110015T HR P20110015 T1 HRP20110015 T1 HR P20110015T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridine
- carboxamide
- phenylimidazo
- group
- imidazo
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- BEHYAANJUKYBTH-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CN21 BEHYAANJUKYBTH-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 30
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 18
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 18
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract 12
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000002253 acid Substances 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 239000000460 chlorine Substances 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 229910052705 radium Inorganic materials 0.000 claims abstract 2
- 229910052701 rubidium Inorganic materials 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims 7
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 claims 3
- -1 6-Chloro-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 6-Methyl-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 6-(Dimethylamino)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound 0.000 claims 3
- LJHNQCYVAAPQRP-UHFFFAOYSA-N 6-(diethylamino)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 6-(3-methylphenyl)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound CCN(CC)c1ccc2nc(cn2c1)C(=O)Nc1ccccc1.Cc1cccc(c1)-c1ccc2nc(cn2c1)C(=O)Nc1ccccc1 LJHNQCYVAAPQRP-UHFFFAOYSA-N 0.000 claims 1
- GEBMQUDYOROJBS-UHFFFAOYSA-N 6-(dimethylamino)-n-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C=1N2C=C(N(C)C)C=CC2=NC=1C(=O)NC1=CC=CC(C(F)(F)F)=C1 GEBMQUDYOROJBS-UHFFFAOYSA-N 0.000 claims 1
- ZWVHKKAQJYXIQM-UHFFFAOYSA-N 6-[3-(methylcarbamoyl)phenyl]-n-phenylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound CNC(=O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C(=O)NC=2C=CC=CC=2)=C1 ZWVHKKAQJYXIQM-UHFFFAOYSA-N 0.000 claims 1
- LTIYHHOHZJJBFX-UHFFFAOYSA-N 6-acetyl-n-phenylimidazo[1,2-a]pyridine-2-carboxamide;hydrochloride Chemical compound Cl.C=1N2C=C(C(=O)C)C=CC2=NC=1C(=O)NC1=CC=CC=C1 LTIYHHOHZJJBFX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- OYBOJNAICFLAPF-UHFFFAOYSA-N C(#C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound C(#C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 OYBOJNAICFLAPF-UHFFFAOYSA-N 0.000 claims 1
- AFNMSNLRYWPNCR-UHFFFAOYSA-N C(=C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(C2=CC=CC=C2)(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.FC1=CC=C(C=C1)NC(=O)C=1N=C2N(C=C(C=C2)C(C)(C)O)C1 Chemical compound C(=C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(C2=CC=CC=C2)(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.FC1=CC=C(C=C1)NC(=O)C=1N=C2N(C=C(C=C2)C(C)(C)O)C1 AFNMSNLRYWPNCR-UHFFFAOYSA-N 0.000 claims 1
- REOYUERTXYVOKC-UHFFFAOYSA-N C(=O)C=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(=O)C2=C(C=CC=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.OCC1=CC=C(C=C1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound C(=O)C=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.C(=O)C2=C(C=CC=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.OCC1=CC=C(C=C1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 REOYUERTXYVOKC-UHFFFAOYSA-N 0.000 claims 1
- CKZATUMGRJAZLJ-UHFFFAOYSA-N C(C)(=O)C=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.N(C2=CC=CC=C2)C(=O)C=2N=C1N(C=C(C=C1)C=1C=C(C(=O)OC)C=CC1)C2.CC2=C(C=CC=1N2C=C(N1)C(=O)NC1=CC=CC=C1)C Chemical compound C(C)(=O)C=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.N(C2=CC=CC=C2)C(=O)C=2N=C1N(C=C(C=C1)C=1C=C(C(=O)OC)C=CC1)C2.CC2=C(C=CC=1N2C=C(N1)C(=O)NC1=CC=CC=C1)C CKZATUMGRJAZLJ-UHFFFAOYSA-N 0.000 claims 1
- XELWDPKVWRLXGE-UHFFFAOYSA-N C(C)(=O)NC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OC(C)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound C(C)(=O)NC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OC(C)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 XELWDPKVWRLXGE-UHFFFAOYSA-N 0.000 claims 1
- NBCRAXITIQGRSB-UHFFFAOYSA-N C1(=CC=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C=C)C1.C1(=CC=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC=CC=C2)C1.ClC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=C(C=CC=C2)Cl Chemical compound C1(=CC=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C=C)C1.C1(=CC=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC=CC=C2)C1.ClC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=C(C=CC=C2)Cl NBCRAXITIQGRSB-UHFFFAOYSA-N 0.000 claims 1
- YJRJKJVXHLVCPZ-UHFFFAOYSA-N CC(O)c1cccc(c1)-c1ccc2nc(cn2c1)C(=O)Nc1ccccc1.NC(=O)c1cccc(c1)-c1ccc2nc(cn2c1)C(=O)Nc1ccccc1 Chemical compound CC(O)c1cccc(c1)-c1ccc2nc(cn2c1)C(=O)Nc1ccccc1.NC(=O)c1cccc(c1)-c1ccc2nc(cn2c1)C(=O)Nc1ccccc1 YJRJKJVXHLVCPZ-UHFFFAOYSA-N 0.000 claims 1
- LHXXNWRUCPJMLF-UHFFFAOYSA-N CC1=CC=CC=2N1C=C(N2)C(=O)NC2=CC=CC=C2.CC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.CN(C=1C=CC=2N(C1C)C=C(N2)C(=O)NC2=CC=CC=C2)C Chemical compound CC1=CC=CC=2N1C=C(N2)C(=O)NC2=CC=CC=C2.CC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.CN(C=1C=CC=2N(C1C)C=C(N2)C(=O)NC2=CC=CC=C2)C LHXXNWRUCPJMLF-UHFFFAOYSA-N 0.000 claims 1
- GRWBRUBFWIQHJX-UHFFFAOYSA-N CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)C)C.ClC=2C(=C(C=CC2)NC(=O)C=2N=C1N(C=C(C=C1)C1=CC(=CC=C1)CO)C2)F Chemical compound CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)C)C.ClC=2C(=C(C=CC2)NC(=O)C=2N=C1N(C=C(C=C1)C1=CC(=CC=C1)CO)C2)F GRWBRUBFWIQHJX-UHFFFAOYSA-N 0.000 claims 1
- BJSHMZLZUNRCGU-UHFFFAOYSA-N CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)F)C.C(N)(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 Chemical compound CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)F)C.C(N)(=O)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 BJSHMZLZUNRCGU-UHFFFAOYSA-N 0.000 claims 1
- YELHDPMJMMZWCD-UHFFFAOYSA-N CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)OC(F)(F)F)C.ClC2=C(C=CC=C2)NC(=O)C=2N=C1N(C=C(C=C1)N(C)C)C2 Chemical compound CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)OC(F)(F)F)C.ClC2=C(C=CC=C2)NC(=O)C=2N=C1N(C=C(C=C1)N(C)C)C2 YELHDPMJMMZWCD-UHFFFAOYSA-N 0.000 claims 1
- XDBGNGMAOKVBFP-UHFFFAOYSA-N COC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.CC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.FC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound COC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.CC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.FC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 XDBGNGMAOKVBFP-UHFFFAOYSA-N 0.000 claims 1
- JPCVNWUZORYLLK-UHFFFAOYSA-N COC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OCC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(#N)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound COC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OCC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.C(#N)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 JPCVNWUZORYLLK-UHFFFAOYSA-N 0.000 claims 1
- 208000022306 Cerebral injury Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DZXDJCOJUIAQRT-UHFFFAOYSA-N ClC1=C(C=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 Chemical compound ClC1=C(C=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 DZXDJCOJUIAQRT-UHFFFAOYSA-N 0.000 claims 1
- BFRCDCMSKRWOCD-UHFFFAOYSA-N ClC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.NCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 Chemical compound ClC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.NCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 BFRCDCMSKRWOCD-UHFFFAOYSA-N 0.000 claims 1
- XASWHBCUVYDCFQ-UHFFFAOYSA-N ClC=1C=CC(=C(C1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1)F.ClC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1 Chemical compound ClC=1C=CC(=C(C1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1)F.ClC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1 XASWHBCUVYDCFQ-UHFFFAOYSA-N 0.000 claims 1
- GRJUMYIQVCNBNZ-UHFFFAOYSA-N ClC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=C(C=C2)Cl.ClC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=C(C=C1)N(C)C Chemical compound ClC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=C(C=C2)Cl.ClC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=C(C=C1)N(C)C GRJUMYIQVCNBNZ-UHFFFAOYSA-N 0.000 claims 1
- BKXMLRITJVEYLB-UHFFFAOYSA-N FC1=C(C=C(C=C1)F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)C Chemical compound FC1=C(C=C(C=C1)F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC(=CC=C2)C BKXMLRITJVEYLB-UHFFFAOYSA-N 0.000 claims 1
- FOPKPKOOWUYQQY-UHFFFAOYSA-N FC1=C(C=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.FC1=C(C=CC=C1F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 Chemical compound FC1=C(C=CC=C1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.FC1=C(C=CC=C1F)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 FOPKPKOOWUYQQY-UHFFFAOYSA-N 0.000 claims 1
- TXNPDLASUGMHSF-UHFFFAOYSA-N FC1=CC=C(C=C1)NC(=O)C=1N=C2N(C=C(C=C2)C(=C)C)C1.OC(C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound FC1=CC=C(C=C1)NC(=O)C=1N=C2N(C=C(C=C2)C(=C)C)C1.OC(C)(C)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2 TXNPDLASUGMHSF-UHFFFAOYSA-N 0.000 claims 1
- JEZWSSDOPWFTDJ-UHFFFAOYSA-N FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)I)C1.IC=1C=CC=2N(C1C)C=C(N2)C(=O)NC2=CC=CC=C2.N2(CCC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 Chemical compound FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)I)C1.IC=1C=CC=2N(C1C)C=C(N2)C(=O)NC2=CC=CC=C2.N2(CCC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 JEZWSSDOPWFTDJ-UHFFFAOYSA-N 0.000 claims 1
- KMEZENUTTJRIRO-UHFFFAOYSA-N FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1.ClC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 Chemical compound FC=1C=C(C=C(C1)F)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1.ClC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1 KMEZENUTTJRIRO-UHFFFAOYSA-N 0.000 claims 1
- KZXLZYDINXQBHC-UHFFFAOYSA-N FC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=C(C=CC=C2)F)C Chemical compound FC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)CO)C1.CN(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=C(C=CC=C2)F)C KZXLZYDINXQBHC-UHFFFAOYSA-N 0.000 claims 1
- KEMFSVLMLCQIAQ-UHFFFAOYSA-N FC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.BrC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.CC1=CC=2N(C=C1)C=C(N2)C(=O)NC2=CC=CC=C2 Chemical compound FC=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.BrC=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1.CC1=CC=2N(C=C1)C=C(N2)C(=O)NC2=CC=CC=C2 KEMFSVLMLCQIAQ-UHFFFAOYSA-N 0.000 claims 1
- ICFCQBOWXWGCJV-UHFFFAOYSA-N N-(3-chloro-2-fluorophenyl)-6-(dimethylamino)imidazo[1,2-a]pyridine-2-carboxamide N-[3-(difluoromethoxy)phenyl]-6-(dimethylamino)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound FC(OC=1C=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1)F.ClC=1C(=C(C=CC1)NC(=O)C=1N=C2N(C=C(C=C2)N(C)C)C1)F ICFCQBOWXWGCJV-UHFFFAOYSA-N 0.000 claims 1
- BQKFKIFSXKOKDS-UHFFFAOYSA-N N1(CCOCC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.ClC=2C=CC(=C(C2)NC(=O)C=2N=C1N(C=C(C=C1)C1=CC(=CC=C1)CO)C2)F Chemical compound N1(CCOCC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.ClC=2C=CC(=C(C2)NC(=O)C=2N=C1N(C=C(C=C1)C1=CC(=CC=C1)CO)C2)F BQKFKIFSXKOKDS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- UKQPYPFTSUNKJJ-UHFFFAOYSA-N OC(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2)C2=CC=CC=C2.OC(C)(C)C=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 Chemical compound OC(C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2)C2=CC=CC=C2.OC(C)(C)C=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 UKQPYPFTSUNKJJ-UHFFFAOYSA-N 0.000 claims 1
- JYFWRZSLYABYED-UHFFFAOYSA-N OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OCC2=C(C=CC=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C(=O)NC2=CC=CC=C2.OCC2=C(C=CC=C2)C=2C=CC=1N(C2)C=C(N1)C(=O)NC1=CC=CC=C1 JYFWRZSLYABYED-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- NWJXSOPECLIQJJ-UHFFFAOYSA-N n-(2,5-difluorophenyl)-6-(dimethylamino)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C=1N2C=C(N(C)C)C=CC2=NC=1C(=O)NC1=CC(F)=CC=C1F NWJXSOPECLIQJJ-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0606012A FR2903107B1 (fr) | 2006-07-03 | 2006-07-03 | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| PCT/FR2007/001125 WO2008003856A1 (fr) | 2006-07-03 | 2007-07-03 | Dérivés d'imidazo[1,2-a]pyridine-2-carboxamides leur préparation et leur application en thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110015T1 true HRP20110015T1 (hr) | 2011-02-28 |
Family
ID=37775231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110015T HRP20110015T1 (hr) | 2006-07-03 | 2011-01-11 | DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7704989B2 (es) |
| EP (1) | EP2041133B1 (es) |
| JP (1) | JP5259587B2 (es) |
| KR (1) | KR20090024776A (es) |
| CN (1) | CN101484453B (es) |
| AT (1) | ATE484504T1 (es) |
| AU (1) | AU2007271008B2 (es) |
| BR (1) | BRPI0714320A2 (es) |
| CA (1) | CA2655713C (es) |
| CY (1) | CY1111868T1 (es) |
| DE (1) | DE602007009839D1 (es) |
| DK (1) | DK2041133T3 (es) |
| ES (1) | ES2354482T3 (es) |
| FR (1) | FR2903107B1 (es) |
| HK (1) | HK1135964A1 (es) |
| HR (1) | HRP20110015T1 (es) |
| IL (1) | IL195891A0 (es) |
| MX (1) | MX2008016546A (es) |
| PL (1) | PL2041133T3 (es) |
| PT (1) | PT2041133E (es) |
| RS (1) | RS51652B (es) |
| RU (1) | RU2441003C2 (es) |
| SI (1) | SI2041133T1 (es) |
| WO (1) | WO2008003856A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| JP5520831B2 (ja) * | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| FR2925906B1 (fr) * | 2008-01-02 | 2010-08-20 | Sanofi Aventis | COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2925905B1 (fr) | 2008-01-02 | 2010-11-05 | Sanofi Aventis | DERIVES DE 2-BENZOYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2925900B1 (fr) * | 2008-01-02 | 2011-03-04 | Sanofi Aventis | DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2925901B1 (fr) * | 2008-01-02 | 2011-03-04 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2925903B1 (fr) * | 2008-01-02 | 2011-01-21 | Sanofi Aventis | DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2928921B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| FR2928923B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2933609B1 (fr) | 2008-07-10 | 2010-08-27 | Fournier Lab Sa | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
| WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US9238647B2 (en) | 2009-03-23 | 2016-01-19 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| FR2950053B1 (fr) | 2009-09-11 | 2014-08-01 | Fournier Lab Sa | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
| FR2955110A1 (fr) | 2010-01-08 | 2011-07-15 | Fournier Lab Sa | Nouveaux derives de type pyrrolopyridine benzoique |
| ES2573148T3 (es) * | 2010-08-25 | 2016-06-06 | Neopharm Co., Ltd. | Compuestos y composición de 1H-benzo[d]imidazol-5-ilo para el tratamiento de enfermedades inflamatorias |
| EP2939675B1 (en) * | 2012-12-28 | 2019-09-04 | Shin Nippon Biomedical Laboratories, Ltd. | Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2638161B1 (fr) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| US6489337B1 (en) | 2000-03-31 | 2002-12-03 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating histamine H3 receptor-mediated disorders with 2- or 3-aryl substituted imidazo[1,2-a] pyridines |
| DE10117184A1 (de) | 2001-04-05 | 2002-10-17 | Gruenenthal Gmbh | Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen |
| CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| JP2006522794A (ja) | 2003-04-10 | 2006-10-05 | ファイザー株式会社 | Ｎｒ２ｂ受容体拮抗物質としての二環系化合物 |
| AU2004276337B2 (en) * | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| US7767670B2 (en) * | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
| CA2577275A1 (en) * | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| ATE427946T1 (de) * | 2004-12-22 | 2009-04-15 | Astrazeneca Ab | Pyridincarbonsaureamidderivate zur verwendung als antikrebsmittel |
| AR053992A1 (es) * | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
-
2006
- 2006-07-03 FR FR0606012A patent/FR2903107B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-03 EP EP07803833A patent/EP2041133B1/fr active Active
- 2007-07-03 PT PT07803833T patent/PT2041133E/pt unknown
- 2007-07-03 DK DK07803833.8T patent/DK2041133T3/da active
- 2007-07-03 CA CA2655713A patent/CA2655713C/fr not_active Expired - Fee Related
- 2007-07-03 RS RS20110009A patent/RS51652B/en unknown
- 2007-07-03 JP JP2009517332A patent/JP5259587B2/ja not_active Expired - Fee Related
- 2007-07-03 BR BRPI0714320-6A2A patent/BRPI0714320A2/pt not_active IP Right Cessation
- 2007-07-03 AT AT07803833T patent/ATE484504T1/de active
- 2007-07-03 PL PL07803833T patent/PL2041133T3/pl unknown
- 2007-07-03 WO PCT/FR2007/001125 patent/WO2008003856A1/fr active Application Filing
- 2007-07-03 ES ES07803833T patent/ES2354482T3/es active Active
- 2007-07-03 SI SI200730465T patent/SI2041133T1/sl unknown
- 2007-07-03 KR KR1020097000050A patent/KR20090024776A/ko not_active Application Discontinuation
- 2007-07-03 CN CN200780025234XA patent/CN101484453B/zh not_active Expired - Fee Related
- 2007-07-03 MX MX2008016546A patent/MX2008016546A/es active IP Right Grant
- 2007-07-03 AU AU2007271008A patent/AU2007271008B2/en not_active Ceased
- 2007-07-03 RU RU2009103307/04A patent/RU2441003C2/ru not_active IP Right Cessation
- 2007-07-03 DE DE602007009839T patent/DE602007009839D1/de active Active
-
2008
- 2008-12-11 IL IL195891A patent/IL195891A0/en unknown
- 2008-12-17 US US12/337,007 patent/US7704989B2/en not_active Expired - Fee Related
-
2010
- 2010-01-05 HK HK10100041.7A patent/HK1135964A1/xx not_active IP Right Cessation
- 2010-02-24 US US12/711,779 patent/US8404848B2/en not_active Expired - Fee Related
-
2011
- 2011-01-11 HR HR20110015T patent/HRP20110015T1/hr unknown
- 2011-01-12 CY CY20111100038T patent/CY1111868T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5259587B2 (ja) | 2013-08-07 |
| CA2655713C (fr) | 2015-05-05 |
| FR2903107B1 (fr) | 2008-08-22 |
| DK2041133T3 (da) | 2011-02-07 |
| DE602007009839D1 (de) | 2010-11-25 |
| US20090149441A1 (en) | 2009-06-11 |
| PL2041133T3 (pl) | 2011-04-29 |
| RU2441003C2 (ru) | 2012-01-27 |
| MX2008016546A (es) | 2009-02-06 |
| CN101484453A (zh) | 2009-07-15 |
| AU2007271008A1 (en) | 2008-01-10 |
| US8404848B2 (en) | 2013-03-26 |
| HK1135964A1 (en) | 2010-06-18 |
| PT2041133E (pt) | 2011-01-10 |
| RU2009103307A (ru) | 2010-08-10 |
| IL195891A0 (en) | 2009-09-01 |
| KR20090024776A (ko) | 2009-03-09 |
| CY1111868T1 (el) | 2015-11-04 |
| CA2655713A1 (fr) | 2008-01-10 |
| FR2903107A1 (fr) | 2008-01-04 |
| ATE484504T1 (de) | 2010-10-15 |
| US20100168155A1 (en) | 2010-07-01 |
| EP2041133A1 (fr) | 2009-04-01 |
| US7704989B2 (en) | 2010-04-27 |
| AU2007271008B2 (en) | 2012-10-11 |
| CN101484453B (zh) | 2012-07-04 |
| ES2354482T3 (es) | 2011-03-15 |
| EP2041133B1 (fr) | 2010-10-13 |
| BRPI0714320A2 (pt) | 2014-06-24 |
| JP2009541471A (ja) | 2009-11-26 |
| SI2041133T1 (sl) | 2011-02-28 |
| RS51652B (en) | 2011-10-31 |
| WO2008003856A1 (fr) | 2008-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110015T1 (hr) | DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI | |
| WO2020261114A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| CA2993304C (en) | Novel compounds as ror gamma modulators | |
| US20230192645A1 (en) | Indole carboxamide compounds | |
| HRP20230201T1 (hr) | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste | |
| JP2018505898A5 (es) | ||
| KR102069730B1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
| JP2010505794A5 (es) | ||
| SE0202134D0 (sv) | Therapeutic agents | |
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| AR036233A1 (es) | Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| NZ612041A (en) | Compounds and their use as bace inhibitors | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| JP2023527010A (ja) | 化合物 | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| EA031201B1 (ru) | Соединения имидазопиридазина | |
| HRP20211277T1 (hr) | Predlijek derivata aminokiseline | |
| JP2019537592A5 (es) | ||
| RU2017104264A (ru) | 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные | |
| JP2007500168A5 (es) | ||
| HRP20100604T1 (hr) | Derivati 4h-1,2,4-triazin-5-ona, njihova priprava i njihova uporaba kao alfa 7 nikotinskih acetilkolinskih receptora | |
| JP2019537581A5 (es) |